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Abstract
Introduction: Altered expression of Septin 9 (SEPT9), a septin coding for multiple isoform variants, has been
observed in several carcinomas, including colorectal, head and neck, ovarian and breast, compared to normal
tissues. The mechanisms regulating its expression during tumor initiation and progression in vivo and the
oncogenic function of its different isoforms remain elusive.
Methods: Using an integrative approach, we investigated SEPT9 at the genetic, epigenetic, mRNA and protein
levels in breast cancer. We analyzed a panel of breast cancer cell lines, human primary tumors and corresponding
tumor-free areas, normal breast tissues from reduction mammoplasty patients, as well as primary mammary gland
adenocarcinomas derived from the polyoma virus middle T antigen, or PyMT, mouse model. MCF7 clones
expressing individual GFP-tagged SEPT9 isoforms were used to determine their respective intracellular distributions
and effects on cell migration.
Results: An overall increase in gene amplification and altered expression of SEPT9 were observed during breast
tumorigenesis. We identified an intragenic alternative promoter at which methylation regulates SEPT9_v3
expression. Transfection of specific GFP-SEPT9 isoforms in MCF7 cells indicates that these isoforms exhibit
differential localization and affect migration rates. Additionally, the loss of an uncharacterized SEPT9 nucleolar
localization is observed during tumorigenesis.
Conclusions: In this study, we found conserved in vivo changes of SEPT9 gene amplification and overexpression
during human and mouse breast tumorigenesis. We show that DNA methylation is a prominent mechanism
responsible for regulating differential SEPT9 isoform expression and that breast tumor samples exhibit distinctive
SEPT9 intracellular localization. Together, these findings support the significance of SEPT9 as a promising tool in
breast cancer detection and further emphasize the importance of analyzing and targeting SEPT9 isoform-specific
expression and function.
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Introduction
Identification of biomarkers for early detection and new
therapeutic targets of breast cancer helps to continu-
ously reduce the morbidity of this frequent pathology in
women. This entails resolving the physiological, cellular
and molecular processes underlying the complexity of
breast tumor development and associated tumor hetero-
geneity. One of the main sources of biomarkers and tar-
geted chemotherapy is the cytoskeleton. Cytoskeleton-
associated proteins are frequently misregulated during
cancer initiation and progression and thus contribute to
cancer cell proliferation, migration and invasion [1].
Septin guanosine triphosphatases that assemble into fila-
ments represent such proteins. We previously identified
Septin 9 (SEPT9), a cytoskeletal component [2], as a
* Correspondence: cristina.montagna@einstein.yu.edu
† Contributed equally
1Department of Genetics, Albert Einstein College of Medicine, Yeshiva
University, 1301 Morris Park Avenue, Bronx, NY 10461, USA
Full list of author information is available at the end of the article
Connolly et al. Breast Cancer Research 2011, 13:R76
http://breast-cancer-research.com/content/13/4/R76
© 2011 Connolly et al.; licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
potential oncogene in breast tumorigenesis [3]. Analysis
of a limited set of mouse mammary gland (MG) adeno-
carcinomas proposed SEPT9 as a novel oncogene
because of its high level of genomic amplification in the
form of double-minute chromosomes and jumping
translocations. Such cytogenetic alterations act as a
means of amplification for strong oncogenes, resulting
in their overexpression and gain of function [4]. The
role of SEPT9 as an oncogene is also supported by the
findings that this locus is a hot spot for viral insertions
that cause mouse T-cell lymphoma [5,6], and in human
acute myeloid leukemia this gene is found to be a fusion
partner of mixed lineage leukemia [7,8]. Since our origi-
nal report, other research groups have shown that
amplification and/or overexpression of SEPT9 occurs in
ovarian carcinoma [9-11], head and neck cancer [12,13]
and prostate cancer [14,15]. Additionally, SEPT9 down-
regulation results in the arrest of cell division in human
mammary epithelial cells and human cancer cell lines
[16,17].
The importance of SEPT9 as an early detection mar-
ker has recently been highlighted by the development of
the diagnostic blood-based test for methylated SEPT9
DNA in colon cancer patients [18]. Nevertheless, the
molecular mechanisms underlying the role of SEPT9 in
tumor development are still largely unknown because of
the expression of multiple isoforms [19], along with the
fact that their modes of regulation have yet to be estab-
lished. The oncogenic function of SEPT9 in vivo is still
unclear, although SEPT9_v1 in particular has recently
been shown to promote tumor growth by inducing
angiogenesis via the stabilization of hypoxia-inducible
factor-1 alpha (HIF-1a) in a heterotransplant model
[14]. Other studies using breast nontumorigenic and
cancer cell lines have indicated that different SEPT9 iso-
forms may have distinct cellular functions [20,21].
We performed a comprehensive and integrative analy-
sis of SEPT9 gene amplification, expression at the
mRNA and protein levels, and epigenetic profiling using
a panel of human breast cell lines, tissues from breast
cancer patients with premalignant lesions and primary
adenocarcinomas, and normal breast tissue derived from
reduction mammoplasty patients. We also used a mouse
model for mammary tumorigenesis to examine progres-
sive changes in Sept9 gene amplification and expression.
Our data show that altered expression of SEPT9 iso-
forms is associated with stages of breast tumorigenesis
and that changes in the isoform expression pattern do
not occur solely by alternative splicing. DNA methyla-
tion of a putative alternative promoter region within
SEPT9 demonstrates a regulatory mechanism that is
responsible for the differing expression of at least one
isoform in normal and cancer cells. In MCF7 clones
expressing individual GFP-SEPT9 isoforms, we observed
differential cytoplasmic versus nuclear SEPT9 localiza-
tion corresponding to varying migration rates. Further-
more, in addition to its cytoplasmic localization, SEPT9
was also present in the nucleoli of human and mouse
normal mammary epithelial cells, a localization that was
lost in mammary carcinoma cells.
Collectively, our results demonstrate that SEPT9 is a
marker for breast cancer that is worth investigating in
large cohorts of patients and other cancer types. Such
analysis will help to establish the significant genetic, epi-
genetic and proteomic signatures of SEPT9 in breast
cancer and provide the basis for its use in early detec-
tion tests.
Materials and methods
Patient clinical data
Fluorescence in situ hybridization (FISH) and immuno-
fluorescence analysis using tissue microarrays (TMAs)
have been described previously [22]. Flash-frozen nor-
mal breast tissue, breast tumors and matching adjacent
tumor-free areas used for real-time qRT-PCR and DNA
methylation analysis were either collected at Jacobi
Medical Hospital, kindly provided by Dr. Adrian L. Har-
ris (Weatherall Institute of Molecular Medicine, Univer-
sity of Oxford, Oxford, UK), or obtained from the
Cooperative Human Tissue Network (Additional file 1,
Supplementary Table 1). The samples obtained for this
study are part of an approved protocol for the collection
of breast tissue samples (CCI protocol 2007-433,
approved by the Albert Einstein College of Medicine
Committee on Clinical Investigations) and were gener-
ated from leftover biopsies. Patient consent forms were
obtained in compliance with the Declaration of Helsinki.
Mouse mammary gland adenocarcinomas
Mouse primary tumors were dissected from polyoma
virus middle T antigen (PyMT) mice [23] (gift from Dr.
Jeffrey W. Pollard, AECOM, Bronx, NY, USA) at the
Table 1 Association between disease grade and copy
number
Grade Normal copy
number
1 or 2
extra
copies
3 or 4
extra
copies
> 4 extra
copies
BB (n = 7) 7 0 0 0
DCIS (n = 29) 16 8 4 1
Well diff. (n =
1)
1 0 0 0
Moderately
diff. (n = 13)
2 5 5 1
Poorly diff. (n
= 10)
2 6 1 1
p-value (Exact chi-square test for association) < 0.05; p-value (exact CMH test
for non-zero correlation) = < 0.05
BB: benign breast; DCIS: ductal carcinoma in situ; diff.: differentiated.
Connolly et al. Breast Cancer Research 2011, 13:R76
http://breast-cancer-research.com/content/13/4/R76
Page 2 of 16
indicated time points. Tumor-bearing glands were iso-
lated and cut in half. One portion was processed for
Western blot analysis and genetic studies, and the other
was embedded in paraffin. Four-weeks-old C57B6
female mice serving as normal controls were killed, and
the fourth inguinal MGs were dissected. The use of
murine models for this study was approved by the Insti-
tutional Animal Care and Use Committee at AECOM
(protocol 20090502).
Cell lines
The cell lines used for experiments are shown in Addi-
tional file 1, Supplementary Table 2. MCF10A cells were
cultured as previously reported [24,25], hTERT-HME1
and 184A1 cells were cultured in mammary epithelium
basal medium supplemented with the MEGM BulletKit
(CC-3150; Lonza Group Ltd, Basel, Swtizerland) and all
other cell lines were grown in DMEM supplemented
with 10% fetal bovine serum. Because of the relatively
high level of SEPT9 mRNA in the MCF10A cells, we
analyzed the same cell line obtained from two different
sources, Dr. Rachel Hazan (Department of Pathology,
AECOM, Bronx, NY, USA) and the American Type Cul-
ture Collection (Manassas, VA, USA) (Additional file 1,
Supplementary Table 2). HCT116 is a colorectal cancer
cell line that was included in the analysis as a control
for our DNA methylation data, since its DNA is highly
methylated [26] and because of the prognostic role of
DNA methylation of SEPT9 shown in colon cancer [27].
Fluorescence in situ hybridization analysis of cell lines
and tissue microarrays
Nine bacterial artificial chromosome (BAC) clones map-
ping to SEPT9, HER2 and CEP17 were obtained from
the BACPAC Resources Center (Children’s Hospital
Oakland Research Institute, Oakland, CA, USA). Clones
and their genetic mapping are shown in Additional file
2, Supplementary Figure S1A. BAC clones mapping to
the mouse Sept9 gene were previously reported [3].
DNA isolation, labeling, hybridization and imaging were
performed as described previously [22,28]. Slide imaging
was carried out with a Zeiss Axiovert 200 inverted
microscope (Carl Zeiss MicroImaging, Inc., Thornwood,
NY, USA) using SpectrumOrange (SO ™)-specific
(Abbott Molecular, Des Plaines, IL, USA), Cy5-specific
and 4’, 6-diamidino-2-phenylindole-specific filters
(Chroma Technologies, Bellows Falls, VT, USA).
Twenty-five cells were analyzed for each cell line, and
locus-specific signals for SO (SEPT9) and Cy5 (HER2)
were manually counted and plotted for further analysis.
Unsupervised hierarchical clustering and heat map gen-
eration representing the signals for each cell were per-
formed using R version 2.8 statistical software [29]. On
TMAs, signals within each cell were counted for a
minimum of 20 cells and scored as follows: two copies
for each locus were classified as normal; cells with two
copies of CEP17 and three to four copies of SEPT9 were
classified as low copy number gain (+); cells with loss of
CEP17 and at least two copies of SEPT9 and cells with
two copies of CEP17 and five or more copies of SEPT9
were classified as moderately high copy number gain (+
+); cells with more than five copies of SEPT9 were
scored as high copy number gain (+++).
Fisher’s exact test of independence was used to test
the null hypothesis of no association between grade and
copy number, and the Cochran-Mantel-Haenszel test
(based on Pearson’s r) was generated to test the null
hypothesis of no linear association, given the ordinal
nature of both grade and copy number categories.
Immunofluorescence on tissue sections and cell lines
Human TMAs (previously described), mouse mammary
adenocarcinomas and age-matched normal tissues were
baked at 60°C for 1 hour, deparaffinized in xylene (twice
for 10 minutes each time) and rehydrated in a graded
series of ethanol washes. Antigen retrieval was per-
formed using Vector Antigen Unmasking Solution (H-
3300; Vector Laboratories, Burlingame, CA, USA) for 20
minutes. Incubation with the following antibodies
diluted in 3% goat serum/PBS was performed overnight
at 37°C: anti-SEPT9 polyclonal antibody (gift from Dr.
Koh-ichi Nagata, Institute for Developmental Research,
Aichi, Japan [16]) detected with anti-rabbit Alexa Fluor
680 dye (Invitrogen, Carlsbad, CA, USA), monoclonal
anti a-tubulin (DM1A clone; Sigma-Aldrich, St Louis,
MO, USA) detected with anti-mouse Alexa Fluor 488
dye (Invitrogen); anti-nucleolin (gift of Dr. Thomas
Meier, Department of Anatomy & Structural Biology,
AECOM) detected with anti-mouse Alexa Fluor 488 dye
(Invitrogen). All primary antibodies were used at a
1:1,000 dilution.
Stable MCF7 transfectants expressing GFP-tagged iso-
forms of SEPT9 were fixed in 3.7% formaldehyde for 10
minutes at room temperature. All images were acquired
with an Olympus BX61 inverted microscope equipped
with a UPlanSApo 63 × objective oil immersion lens
(Olympus Imaging America, Inc., Melville, NY, USA), a
mercury arc lamp for excitation, narrow band filters for
all fluorescence emission, and a SensiCamQE CCD cam-
era system (PCO AG, Kelheim, Germany) using a FISH
view.
Real-Time qRT-PCR
Total RNA was isolated from cancer cell lines, tissues
and stably transfected GFP clones as reported previously
[3]. cDNA was reverse-transcribed from 5 μg of total
RNA using random primers and SuperScript II Reverse
Transcriptase (Invitrogen). SEPT9 and GFP primers
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were designed with Primer3 software [30] (Additional
file 1, Supplementary Table 3) along with glyceraldehyde
3-phosphate dehydrogenase (GAPDH) primers.
SEPT9_v1 and SEPT9_v3 isoform primers were either as
published [21] or designed by hand based on unique
sequences at the 5’ end. Real-Rime qRT-PCR was per-
formed using Applied Biosystems Fast SYBR Green
Master Mix and the StepOnePlus Real-Time PCR Sys-
tem (Life Technologies Corp., Carlsbad, CA, USA). Data
normalization and analysis were performed as described
previously [3]. P values for statistically significant differ-
ences in mRNA levels were calculated using a t-test.
Western blot analysis of cell lines and tissues
Proteins (40 μg) were extracted from cell lines and tis-
sues (Additional file 1, Supplementary Table 4) and
separated on 7.5% acrylamide SDS-PAGE gels, then
transferred to nitrocellulose membranes. Alternatively,
NuPAGE Novex 4% to 12% Bis-Tris gradient gel and 3-
(N-morpholino) propanesulfonic acid SDS running buf-
fer (Invitrogen, Cergy-Pontoise, France) were used to
achieve maximal resolution of SEPT9 bands. SEPT9 was
detected by enhanced chemiluminescence using the
anti-SEPT9 antibody (1:4,000 dilution) provided by Dr.
Nagata [31], which recognizes human and mouse
SEPT9_v1 through SEPT9_v4 isoforms and some
uncharacterized high-molecular-weight isoforms; the
antibody provided by Dr. Cossart (Institut Pasteur, Paris,
France [32]) (1:1,000 dilution), which recognizes human
SEPT9_v1 to SEPT9_v5 isoforms; or an antibody that
recognizes only SEPT9_v3 [33] (provided by Dr. Tachi-
bana, Osaka City University, Osaka, Japan) (Additional
file 3, Supplementary Figure S2). Anti-a-tubulin DM1A
antibody was used at a 1:2,000 dilution (Cell Signaling
Technologies, Danvers, MA, USA), and anti-rabbit, anti-
mouse and anti-rat secondary antibodies coupled to
horseradish peroxidase were used at 1:2,000 dilutions
(Jackson Immunoresearch Laboratories, Suffolk, UK).
Quantification of bands was performed with the ImageJ
software package (National Institutes of Health,
Bethesda, MD, USA) and normalized to a-tubulin [34].
All positive bands between 37 and 75 kDa were counted
as the SEPT9-related signal based on the expected mole-
cular weight range defined by the five known isoforms
(Additional file 1, Supplementary Table 5), and this sig-
nal was normalized to the a-tubulin signal at 50 kDa.
Cloning of GFP-SEPT9 isoform fusions and generation of
MCF7 stable transfectant clones
The SEPT9_v1, SEPT9_v2, SEPT9_v3, SEPT9_v4 and
SEPT9_v5 isoforms [GenBank:AF189713, GenBank:
AJ312319, GenBank:AF123052, GenBank:AJ312322 and
GenBank:AJ312320] were cloned from normal breast
cDNA (Clontech Laboratories, Inc., Mountain View,
CA, USA) using an isoform-specific forward primer con-
taining a XhoI cassette and a reverse primer common to
all isoforms containing a HindIII cassette (Additional
file 1, Supplementary Table 3). Two micrograms of iso-
form-specific plasmid were transfected into subconfluent
MCF7 cells using FuGENE 6 Transfection Reagent
(Roche Applied Science Indianapolis, IN, USA). Forty-
eight hours after transfection cells were selected with
800 μg/mL G418 for 14 days. mRNA and protein levels
were quantified for four clones per SEPT9-specific iso-
form (total of 20 clones) by real-time qRT-PCR and
Western blot analysis (Additional file 4, Supplementary
Figure S3).
Cloning of SEPT9_v3 promoter and luciferase assay
The genomic region chr17:72,824,475-72,827,999 of the
hg18 build of the human genome was selected based on
mammalian conservation and the publicly available
ENCODE Project integrated regulation tracks [35]. The
fragments shown in Figure 4B were cloned into the
pGL3-Basic Luciferase Reporter Vector (Promega, Madi-
son, WI, USA) and transfected into MCF7 cells, where
lysates were quantified with the Dual-Luciferase Repor-
ter Assay System (Promega). Data from three technical
and two biological replicates were plotted for a total of
six data points for each fragment.
Quantitative DNA methylation analysis using the
MassARRAY EpiTYPER
Primers within the SEPT9_v3 promoter region were
designed to include and target 10 different CpG sites
using the MethPrimer program (Li Lab, University of
California San Francisco, San Francisco, CA, USA) [36].
Matrix-assisted laser desorption/ionization time-of-flight
mass spectrometry was performed using the MassAR-
RAY EpiTYPER assay platform (SEQUENOM Inc., San
Diego, CA, USA) on bisulfite-converted DNA as pre-
viously described [37]. For bisulfite conversion of DNA,
we used the Zymo DNA purification kit (Zymo Research
Corp., Irvine, CA, USA). MassARRAY primers (SEQUE-
NOM Inc.) were designed to cover the genomic region
HSA17 using the hg17 build of the human genome
(chr17:72,823,233-72,825,460) [38] (Additional file 1,
Supplementary Table 3). For 5-aza-2’-deoxycytidine
treatment, cell lines were plated in 100-mm Petri dishes,
allowed to attach overnight and treated with 2 μM 5-
aza-2’-deoxycytidine for three days. Fresh 5-aza-2’-deox-
ycytidine stock was made every day and replaced
together with media. Statistical analysis of the differ-
ences in methylation percentages between paired tumor
and adjacent normal tissue samples at each CpG site
was performed using nonparametric Wilcoxon signed-
rank tests. P values were adjusted using the Holm-Bon-
ferroni step-down method to correct for multiple testing
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[39]. The average methylation percentage across all CpG
sites was compared in tumors versus tumor-free adja-
cent tissues as well as normal tissues using a paired t-
test. Regression analysis to determine the coefficient of
correlation between SEPT9_v3 mRNA and DNA methy-
lation levels was performed using Microsoft Excel ver-
sion 11.6.3 software (Microsoft Corp., Redmond, WA,
USA).
Migration assay and colony size assessment
Transwell inserts (8 μM; Millipore, Billerica, MA, USA)
were coated with 25 μg/mL type I rat tail collagen (BD
Biosciences Franklin Lakes, NJ, USA). Cells (5 × 104 in
DMEM 0.3% BSA) were added in triplicate for each
sample to the transwell inserts and allowed to migrate
for 10 hours at 37°C. Nonmigratory cells were removed
and filters were fixed in 3.7% formaldehyde/PBS for 15
minutes and stained with 0.2% crystal violet dye for 10
minutes. Migrated cells were counted and averaged
from 10 fields of view per filter at 20 × magnification
using an Axio Observer.A1 inverted microscope (Carl
Zeiss MicroImaging, Inc.). Two independent biological
replicate assays were analyzed. For cluster analysis, cells
were seeded at 3.8 × 103/cm2 and allowed to grow for 5
days. The number of cells comprising clusters found
within one-fourth of a 60-mm plate was counted for
each cell line, again with the Axio Observer.A1 inverted
microscope at 20 × magnification.
Results
To determine how altered SEPT9 DNA copy number in
human breast carcinogenesis might affect gene expres-
sion and protein translation, we performed a compre-
hensive analysis of DNA, mRNA and protein expression
in a panel of 14 established and well-characterized
human breast cancer cell lines. To potentially correlate
in vitro with in vivo findings, 215 samples consisting of
breast tumors, matched tumor-free tissues and normal
breast epithelium were analyzed (Additional file 1, Sup-
plementary Table 1).
SEPT9 is amplified in breast cancer cell lines and human
breast adenocarcinomas
Using FISH to determine DNA copy number, a locus-
specific probe for SEPT9 was cohybridized with a probe
for HER2, a well-established oncogenetic biomarker that
maps to the same chromosome arm as SEPT9 (Addi-
tional file 2, Supplementary Figure S1A). Gene amplifi-
cation of both loci was observed in most cancer cell
lines and human breast carcinoma samples (Figure 1A).
The nontumorigenic epithelial cell line MCF10A exhib-
ited the lowest copy number for both SEPT9 and HER2
oncogenes (2.6 and 2.28 average number of copies per
cell, respectively) (Additional file 2, Supplementary
Figure S1B). The nontumorigenic cell line HBL100,
however, carries a higher average number of copies per
cell for both genes (8.96 and 8.68), which is consistent
with the knowledge that over time, cultured, immorta-
lized cell lines derived from nontumorigenic breast tis-
sue may acquire cytogenetic alterations similar to those
of cancer cell lines [40]. Unsupervised clustering based
on SEPT9 signals counted within each cell separated the
12 cell lines into low and high copy number clusters
(Figure 1B). The low SEPT9 copy number group
included the nontumorigenic HBL100 and MCF10A cell
lines, while the high copy number group included the
highly tumorigenic SKBR3 and MDA-MB-231 cell lines.
Analysis of SEPT9 and HER2 copies for each cell line
within a single cell revealed that the amplification of
SEPT9 and HER2 represents two independent cytoge-
netic events (Additional file 2, Supplementary Figure
S1C).
SEPT9 is overexpressed at the mRNA and protein levels in
breast cancer cell lines and human breast
adenocarcinomas
We aimed to determine whether genomic amplification
of SEPT9 results in increased mRNA levels in human
breast cancer cell lines and whether this change trans-
lates into higher protein levels. Quantification of total
SEPT9 mRNA levels (Figure 1C) showed that the cell
lines expressed variable SEPT9 mRNA levels, but we
found no direct correlation between mRNA levels and
DNA copy number, suggesting that a more complex
mode of regulation might occur at this genomic locus.
Because cytogenetic alterations of cell lines in two-
dimensional culture systems may not accurately reflect
what occurs in vivo, we examined the differences in
SEPT9 expression in normal and tumor human breast
tissues at the mRNA and protein levels. SEPT9 mRNA
expression was quantified in 93 breast tissue samples
consisting of normal tissue from individuals who had
undergone reduction mammoplasty and tumors and
their corresponding adjacent tumor-free breast tissue
from cancer patients. There was a significant increase in
SEPT9 in tumor tissues compared to both normal and
tumor-free adjacent tissues (Figure 2A). Additionally, we
analyzed SEPT9 protein content in breast tissues and
tumors and found a significant increase in SEPT9 pro-
tein expression in tumors compared to normal tissues
(Figure 2B and Additional file 5, Figure Supplementary
S4B). Notably, we found higher expression in adjacent
tumor-free tissues compared to normal tissues. This
result suggests that either (1) SEPT9 protein expression
might be influenced by the tumor microenvironment,
thus affecting the adjacent tumor-free area of the breast,
or (2) SEPT9 expression is altered early in the premalig-
nant stage.
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SEPT9 gene amplification and expression changes during
breast tumor progression
The observed differences in SEPT9 gene amplification
and mRNA and protein levels in breast tumors com-
pared to normal breast tissues prompted us to test
whether these changes are associated with tumor grade.
We analyzed SEPT9 copy number in a tumor set
including benign tissues, ductal carcinoma in situ
(DCIS) and breast tumors classified as poorly or moder-
ately differentiated (grade II or III, respectively). For
well-differentiated tumors (grade I), only one sample
was available, and although it was included in the analy-
sis, it was not used to draw conclusions. Only approxi-
mately one-half of the DCIS samples analyzed presented
Figure 1 SEPT9 is amplified in human breast cancer. (A) FISH labeling of SEPT9 gene (green) and HER2 gene (red) in SKBR3 breast cancer
cells (left panel) and primary invasive ductal carcinoma (IDC) breast tissue (right panel). (B) Unsupervised hierarchical clustering of SEPT9 DNA
copy number in human cell lines. Each block represents one cell, and 25 cells were counted for each cell line. (C) Total SEPT9 mRNA levels in
the human cell lines (Additional file 1, Supplementary Table 2).
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Figure 2 SEPT9 is amplified and overexpressed during breast tumorigenesis. (A) SEPT9 mRNA levels quantified in primary breast tumors
(light gray circles), tumor-free adjacent tissues (dark gray) and normal breast tissues from reduction mammoplasty (black circles). (B)
Quantification of SEPT9 protein expression in breast primary tumors (light gray circles), tumor-free adjacent tissues (dark gray circles) and normal
breast tissues from reduction mammoplasty (black circles). (C) Quantification of Sept9 gene copy number in normal mammary tissues and in
primary mammary adenocarcinomas isolated from the PyMT mouse model at various stages of tumorigenesis (MG, normal mammary gland; 6
weeks premalignant hyperplasia, 8.9 weeks adenoma, and 14 and 20 weeks early and late carcinomas, respectively). Legend indicates copy
number categories. (D) Sept9 mRNA levels in PyMT murine normal (black circles) and primary adenocarcinoma (light gray circles) mammary
tissues. (E) Western blot depicting the pattern of Sept9 isoform (top panel) and a-tubulin (bottom panel) expression in normal mammary tissues
and in primary mammary adenocarcinomas isolated from the PyMT mouse model at various stages of tumorigenesis. Values at the bottom
indicate Sept9 expression levels normalized to a-tubulin. Only the bands between 37 and 75 kDa were used for quantification. T47D human
breast cancer cell line in lane 9 was used as a reference to aid in isoform identification. (F) Left and center panels: immunohistofluorescence
labeling of SEPT9 (red) and a-tubulin (green) in normal breast and adenocarcinoma tissues. White arrowheads indicate SEPT9 nuclear staining.
Right panel: Colocalization of SEPT9 (red) and nucleolin (green) in normal breast tissues.
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normal SEPT9 copy numbers, suggesting that genomic
amplification of this oncogene occurs during early stages
of tumorigenesis (Table 1). The maximum copy number
detected in the primary tumors indicated that there are
lower levels of gene amplification than those observed
in breast cancer cell lines. The most significant finding
of this analysis was that SEPT9 copy number increased
in grades II and III, suggesting that high SEPT9 amplifi-
cation correlates with poor clinical outcome.
To further examine whether SEPT9 gene amplification
and increased SEPT9 mRNA and protein levels occur
during tumor progression, we used the mammary carci-
noma PyMT mouse model [41] to analyze stage-specific
Sept9 expression. We detected Sept9 amplification in
MGs with premalignant adenomas and observed that
Sept9 gain (five signals per cell and higher) increases in
advanced stage IV adenocarcinomas (Figure 2C). Simi-
larly to human primary tumors, murine MG adenocarci-
nomas also expressed higher Sept9 mRNA (Figure 2D)
and protein levels (Figure 2E) than normal MGs. At the
protein level, a differential pattern of Sept9 isoform
expression was reproducibly observed in normal tissue,
hyperplastic tissue, adenoma and early and late carcino-
mas. There was an increase in Sept9 protein expression
compared to normal MGs as early as the hyperplasia
stage (six weeks). The most striking difference was a
prominent decrease in the expression of a 120-kDa
band with a concomitant increase in the expression of a
90-kDa band beyond hyperplasia (Figure 2E). Because
these bands did not match any known isoform of Sept9,
they were excluded from the quantification of Sept9
protein expression levels.
The observed quantitative changes in SEPT9 expres-
sion between normal tissue and breast tumors and dur-
ing tumor progression impelled us to perform
immunofluorescence on the same TMAs used for FISH
to detect whether significant changes in SEPT9 intracel-
lular localization occurred. All cells expressed character-
istic SEPT9 cytoplasmic staining, but, surprisingly,
normal breast tissues bore a strong nuclear signal in the
luminal layer of the epithelium that was lost in tumor
cells (Figure 2F and Additional file 1, Supplementary
Table 6). We also analyzed MGs isolated from four-
week-old virgin C57B6 mice and found similar intracel-
lular localization (Additional file 1, Supplementary Table
6). Additionally, when we analyzed PyMT tissues at var-
ious stages of tumorigenesis, we found that approxi-
mately 40% of cells (all luminal) exhibited nuclear
staining in hyperplasia, whereas only about 2% of cells
carried a nucleolar signal in advanced tumor stages. On
the basis of the morphology and size of the nuclear
staining, it appears that SEPT9 localizes to the nucleolus
of normal breast cells, which was confirmed by its colo-
calization with nucleolin (Figure 2F). Collectively, these
results suggest that in normal breast tissue, SEPT9
maintains both cytoplasmic and nucleolar localization,
whereas during tumorigenesis only cytoplasmic expres-
sion is retained.
Hypermethylation of the SEPT9_v3 putative promoter is
frequent in breast tumors and results in SEPT9_v3
silencing
The lack of a direct correlation between SEPT9 copy
number increases and mRNA levels prompted us to
examine epigenetic modifications, specifically DNA
methylation, at potential alternative transcription start
sites (TSSs) in breast cancer. Alternative splicing of
SEPT9 mRNA has previously been proposed as the pri-
mary mode of regulation of SEPT9 isoforms [19].
Recently, it has been suggested that DNA methylation
of CpG sites near specific TSSs coding for individual
isoform variants may be an alternative regulatory
mechanism [18]. On the basis of our genomic and
computational analyses of the mammalian SEPT9 gene,
we found a highly conserved genomic region contain-
ing a CpG island that maps upstream to the SEPT9_v3
start codon, suggesting the presence of an alternative
promoter (Figure 3A, top). We designed specific pri-
mers that targeted and quantified the methylation per-
centage at each CG dinucleotide within this region by
using the highly sensitive MassARRAY technique on
our panel of cell lines. Cell lines clustered into two
groups, one group with the SEPT9_v3 TSS hypomethy-
lated (average 18.4% methylation across all CpG sites)
and one group with the SEPT9_v3 TSS hypermethy-
lated (76.4%) (Figure 3A). To determine how DNA
methylation alters SEPT9_v3 transcription, we quanti-
fied specific SEPT9_v1 and SEPT9_v3 mRNA levels in
cell lines, using SEPT9_v1 for comparison since this
specific isoform has been shown to increase in cancer
(Figure 3B). As expected, SEPT9_v1 was expressed in
most cell lines, whereas significant differences in
mRNA levels were observed for the SEPT9_v3 isoform.
A subset of cell lines (T47D, MDA-MB-435, MCF7
and BT474) expressed nearly undetectable levels of
SEPT9_v3, whereas other cell lines (HS578T, HBL100,
MDA-MB-231, MCF10A, SKBR3 and MDA-MB-468)
expressed high levels. Interestingly, cell lines with
hypermethylation at the SEPT9_v3 start site exhibited
lower levels of SEPT9_v3 mRNA, whereas cell lines
with hypomethylation at the SEPT9_v3 start site
expressed higher SEPT9_v3 mRNA levels (R2 = 0.678;
significance deviation from zero: P = 0.0031) (Figures
3A and 3B). This finding also corresponded to repres-
sion of SEPT9_v3 expression at the protein level in cell
lines that exhibited hypermethylation at the SEPT9_v3
start site (Figure 3C and Additional file 5, Supplemen-
tary Figure S4A).
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Figure 3 Hypermethylation of an alternative promoter in breast tumors downregulates SEPT9_v3. (A) Quantification of DNA methylation
at CpG sites upstream of the SEPT9_v3 transcription start site in cell lines targeted by MassARRAY. The unsupervised clustering distributes cell
lines into two groups: hypomethylated and hypermethylated (left panel). Differences in the overall methylation percentages between these two
groups are shown (right panel). White boxes represent CpG sites that were not analyzable. (B) Quantification of SEPT9_v1 and SEPT9_v3 isoform
mRNA levels in human cell lines. (C) Expression of SEPT9 (top panel), SEPT9_v3 isoform (middle panel) and a-tubulin (bottom panel) detected by
Western blot in the panel of breast cancer cell lines. Note that with the labeling of recombinant SEPT9_v1 and _v3 by an antibody recognizing
both of these isoforms [16], the anti-SEPT9_v3 antibody recognizes the bottom band of the high-molecular-weight isoform doublet.
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To confirm the functional consequence of DNA
methylation at the SEPT9_v3 start site on transcription,
a subset of cell lines was treated with the DNA
demethylating agent 5-aza-2’-deoxycytidine. As
expected, treatment of cell lines displaying hypermethy-
lation of the SEPT9_v3 start site resulted in increased
SEPT9_v3 mRNA expression (Figure 4A, left graph),
whereas it had no effect on cell lines exhibiting hypo-
methylation (Figure 4A, right graph). Taken together,
these results strongly indicate that DNA methylation of
an alternative promoter near the SEPT9_v3 TSS is a
principal mechanism responsible for decreased
SEPT9_v3 expression. The presence of an active alterna-
tive promoter (Figure 4B, green bar) was confirmed by
performing a luciferase reporter assay in which the
genomic region upstream of the SEPT9_v3 TSS was tar-
geted (Figure 4B).
Next we analyzed the methylation status of the CpG
sites proximal to the SEPT9_ v3 TSS in human breast
tumor samples, their matching tumor-free adjacent
areas and normal breast tissues from reduction mam-
moplasty patients (Figure 4C). MassARRAY analysis
revealed an overall statistically significant difference in
methylation levels between breast tumor tissues, the
corresponding matching tumor-free area and normal
breast tissues (52.9% versus 41.7% and 44.5%, respec-
tively) (Figure 4C). Moreover, when DNA methylation
was measured at each of the 10 individual CpG sites, we
also found statistically significant differences in methyla-
tion levels between the tumors and the matching
tumor-free tissue samples. These results suggest that
SEPT9_v3 may frequently be silenced in breast tumors
by methylation of its promoter region.
SEPT9 isoforms differ in their respective cellular
distribution and promigratory potential
We sought to determine whether each SEPT9 isoform
has similar intracellular distribution by generating stable
MCF7 clones, each expressing one GFP-tagged SEPT9
isoform (Additional file 4, Supplementary Figure S3). All
GFP-SEPT9 constructs were expressed in septin-like
filamentous form, confirming functionality (Figure 5).
Differences were observed in the organization of SEPT9
filaments between the nuclear region and the rest of the
cytoplasm, thus the distribution of nuclear and cytoplas-
mic immunofluorescence was quantified for each of the
isoform clones. SEPT9_v1 was mainly expressed within
the nucleus, whereas SEPT9_v2 localization was sparse
in that region. The other SEPT9 isoforms were relatively
equally distributed between the nucleus and the rest of
the cytoplasm.
Because of the presumed specific oncogenic nature of
SEPT9_v1 [21] and the differences in interphase cellular
distribution of SEPT9 isoforms, we tested the
promigratory potential of each SEPT9 isoform in our
stable MCF7 clones (Figure 6A). GFP-SEPT9_v1, GFP-
SEPT9_v3, GFP-SEPT9_v4 and GFP-SEPT9_v5 showed
significant increases in the number of migratory cells,
whereas GFP-SEPT9_v2, despite a similar mRNA
expression level of total SEPT9 in cells (Additional file
4, Supplementary Figure S3D), was not as promigratory
as the parental cell line. On the basis of this observation,
we sought to determine whether increased migration is
the result of a loss of cellular interaction, where single-
cell growth is prevalent, as opposed to clustering, a
common characteristic of epithelial cells. We counted
the average number of cells present in a cluster for each
GFP clone after five days of growth (Figure 6B). The
data revealed that parental MCF7 tended to grow in
clusters containing at least 25 cells. The least migratory
isoform (GFP-SEPT9_v2) had the lowest number of cells
per cluster in the 1-5 range compared to those that
were most migratory (GFP-SEPT9_v1, GFP-SEPT9_v3,
GFP-SEPT9_v4 and GFP-SEPT9_v5).
Discussion
In this study, we performed a comprehensive analysis of
the SEPT9 locus at the levels of DNA copy number,
mRNA and protein expression in breast cell lines, nor-
mal human breast and breast tumor tissues, and normal
mouse MGs and adenocarcinomas. We have shown that
in humans, SEPT9 amplification varies at different stages
of breast tumorigenesis and that in the PyMT mouse
model it is dependent on the stepwise progression of
mammary adenocarcinomas. Surprisingly, increases in
SEPT9 gene copy number did not correlate with
increased mRNA or protein expression in breast cell
lines. However, in primary human and mouse tissues,
more moderate SEPT9 gene amplification was observed,
which correlated with elevated levels of SEPT9 mRNA
and protein. Examination of SEPT9 localization by
immunofluorescence to detect human normal breast tis-
sues and breast tumors, as well as normal mouse and
mammary adenocarcinoma sections, revealed that, aside
from cytoplasmic staining, a specific nucleolar localiza-
tion in normal tissue was present, primarily in the lumi-
nal layer of the ductal epithelium. Previous studies have
shown that septins associate with the nuclear protein
anillin during cytokinesis [42,43] and with karyopherins,
a family of proteins involved in nuclear transport and
septin SUMOylation [44]. Septins also interact with
SOCS7 and accumulate in the nucleus to aid in DNA
repair [45]. These studies, together with our results, sug-
gest that septins may be involved in key nuclear pro-
cesses contributing to normal cellular function and
possibly to tumorigenesis.
Multiple modes of regulation are most likely responsi-
ble for controlling SEPT9 isoform expression, one of
Connolly et al. Breast Cancer Research 2011, 13:R76
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Figure 4 Hypermethylation of the SEPT9_v3 promoter occurs in human breast primary carcinomas. (A) Cell lines were treated with 5-aza-
2’-deoxycytidine, and SEPT9_v3 mRNA was quantified. Representative cell lines with hypermethylation (left graph) and hypomethylation (right
graph) of the SEPT9_v3 promoter region are displayed. U: untreated cells; T: treated cells. (B) SEPT9_v3 promoter region activity. Top: Location of
tested luciferase fragments relative to the DMR. Bottom: Quantification of these fragments via luciferase reporter assay. (C) Supervised clustering
of MassARRAY DNA methylation profiles in human primary adenocarcinomas, matching tumor-free areas and normal breast tissues. Right graph:
Average levels of DNA methylation between tumors and tumor-free matching samples show a statistically significant difference.
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Figure 5 SEPT9 isoforms localize in different cellular compartments. Fluorescence microscopy of MCF7 clones expressing individual GFP-
SEPT9 isoforms (gray scale). Expression of GFP-SEPT9 isoform constructs was quantified and plotted as a ratio of intensities measured outside the
region occupied by the nucleus to measurements within the nucleus (bottom right panel). Average ratios located above the dotted line indicate
cytoplasmic expression and those below the line indicate nuclear expression.
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which, as we have shown, is epigenetic silencing via
DNA methylation. A differentially methylated region
(DMR) upstream from the SEPT9_v3 start site was iden-
tified where hypermethylation was shown to correlate
with SEPT9_v3 silencing in cancer cell lines. Hyper-
methylation of this region was also observed in breast
carcinomas. A luciferase reporter assay confirmed the
presence of an active alternative promoter downstream
from the DMR. Further investigation of this region will
help to identify the transcription factors involved in the
expression of SEPT9_v3 and how it is regulated during
breast tumorigenesis. Our results suggest that expres-
sion levels of high-molecular-weight SEPT9 isoforms
might be regulated by methylation at alternative promo-
ter regions, and the current use of the methylation sta-
tus of the SEPT9_v2 putative alternative promoter
region as a marker for the early detection of colon can-
cer highly supports this hypothesis [18,46]. The role of
methylation of CpG islands found in intragenic alterna-
tive promoters has been highlighted in a recent gen-
ome-wide study of the human brain, where this mode of
regulation has been shown to be both tissue- and cell
type-specific and is conserved in mouse [47]. Additional
predicted alternative promoter regions must be studied
to verify whether SEPT9 isoforms are regulated solely by
DNA methylation or by alternative mechanisms as sug-
gested previously [48]. We have found that estrogen
receptor (ER)-positive tumors express significantly
higher levels of SEPT9 mRNA than ER-negative tumors
(data not shown), suggesting that alternative promoters
found within the SEPT9 gene might be differentially
regulated in breast cancer, potentially through epigenetic
modifications or hormonal regulation.
When we compared normal mouse mammary tissue
to mammary adenocarcinomas in PyMT mice, we
observed increased expression of high-molecular-weight
Sept9 isoforms (that is, isoforms SEPT9_v1, SEPT9_v2
and SEPT9_v3) during tumorigenesis. This finding is
comparable to reports that suggest that SEPT9_v1 is
one of the isoforms with oncogenic potential, as proven
by different mechanisms. It stabilizes HIF-1a and
increases during angiogenesis [14], and it stabilizes c-
Jun N-terminal kinase and promotes proliferation [48].
Further identification and detailed mapping of posttran-
slational modifications by mass spectrometry are
required, and they may identify high-molecular-weight
isoforms such as those observed in mouse tissues (90
and 120 kDa). We did not observe a protein band
matching the molecular weight of Sept9_v4 in the
PyMT tissue. This was to be expected, because in the
mouse, a valine residue replaces the first methionine of
human SEPT9_v4. However, the fact that there was no
Sept9_v4 expression in the PyMT mouse model suggests
that SEPT9_v4 is not a key isoform in breast tumor
development.
If different SEPT9 isoforms maintain specific cellular
functions, changes in their respective expression levels
could result in a gain of oncogenic properties. To test
this hypothesis, we generated MCF7 clones expressing
each of five isoforms individually. We observed that
GFP-SEPT9_v1 was primarily localized within the
nucleus, whereas GFP-SEPT9_v2 displayed mainly cyto-
plasmic localization, with the localization of GFP-
SEPT9_v3, GFP-SEPT9_v4, and GFP-SEPT9_v5 being
somewhat evenly distributed between both cellular com-
partments. SEPT9 was initially found to be overex-
pressed in human ovarian tumors with an observed
increase in SEPT9_v1 and SEPT9_v4* isoform expression
[10]. Our data, together with the findings of Petty’s
group [49], suggest that SEPT9_v1 is a key isoform in
Figure 6 SEPT9 isoforms alter migratory properties of MCF7. (A) Transwell migration assay comparing MCF7 clones, each expressing a
different GFP-SEPT9 isoform fusion construct. Plotting reflects the average number of migrated cells from two biological replicate assays
conducted for each isoform. (B) Cell cluster size distribution for each MCF7 clone. The same gray scale is used in (A) and (B) to represent MCF7
and each isoform construct.
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breast tumorigenesis that promotes cell migration. We
observed that SEPT9_v2 influenced MCF7 cell migration
the least and speculate that a regulatory mechanism
such as methylation of its promoter prevents its expres-
sion, and therefore its function, in this cell line. The
role of SEPT9 in the migration of normal and cancer
cells is presumably connected to its association with
microtubules and the actin cytoskeleton [16,31,50].
Intercellular junctions that interact with the cytoskele-
ton appear to be disrupted upon the overexpression of
isoforms, causing an increase in the rate of migration, as
shown by our results. A recent proteomic analysis of
pseudopods isolated from metastatic cancer cell lines
revealed that SEPT9 is enriched in these structures and
that its downregulation induces a mesenchymal-epithe-
lial transition [51], altering migration rates. SEPT9_v1
was found to exhibit nuclear localization and be the
most promigratory isoform, whereas SEPT9_v2 was
localized to the cytoplasm and affected migration rates
the least. Further studies are necessary to determine
whether cellular localization influences migration along
with other cellular functions.
Collectively, our results strongly indicate that SEPT9
plays a role in tumorigenesis and that particular modes
of regulation, such as epigenetic modifications, are
involved in the differential expression of SEPT9 iso-
forms. An intriguing question raised by our study is the
possible connection between the loss of SEPT9 nuclear
localization and tumor development. What determines
this change in intracellular localization, and does it con-
tribute to aneuploidy, apoptosis and/or cancer cell inva-
sion and metastasis? Furthermore, is there a balance in
specific expression of SEPT9 isoforms and/or posttran-
slational modifications that drive localization and onco-
genic potential? Our present and previous observations
[3] indicate that SEPT9 operates as an oncogene in can-
cer cells, but it may also sustain a tumor-suppressing
function when localized in normal epithelial nuclei.
Conclusions
SEPT9 amplification occurs at the DNA level during
human and mouse breast carcinogenesis and results in
an overall increase in SEPT9 mRNA and protein levels.
In this study, we have provided evidence that this pro-
cess is associated with the alteration of SEPT9 isoform
expression between normal and tumor cells in breast
cancer. Moreover, we have shown that SEPT9_v3 iso-
form expression is regulated via DNA methylation at an
alternative promoter, potentially driving changes in iso-
form expression during breast cancer initiation and pro-
gression. Our data support the hypothesis that SEPT9
isoforms maintain functional differences that could be
selected for during tumor development and indicate that
SEPT9 isoform profiling could lead to the development
of additional biomarkers for breast cancer detection,
prognosis and treatment. Therefore, this study provides
a rational framework for further analysis of the expres-
sion of SEPT9 isoforms and their specific functions at
the cellular and molecular levels in breast cancer
development.
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